Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era.
Jordan B FenlonRyan J HuttenSkyler B JohnsonBoyu HuHarsh R ShahDeborah M StephensAmit MaityDavid K GaffneyRanda TaoPublished in: Leukemia & lymphoma (2022)
Radiotherapy (RT) utilization for early-stage, low-grade follicular lymphoma (FL) is low despite treatment guideline recommendations. We compare treatment trends for early-stage FL in the era of involved-site RT and rituximab. We identified 11,645 patients in the National Cancer Database (NCDB) with stage I-II, grade 1-2 nodal or extranodal FL diagnosed 2011-2017, with median follow-up of 44 months. From 2011 to 2017, RT utilization rates decreased from 33.4% to 22.4%, observation decreased from 65.3% to 49.7%, chemoimmunotherapy increased from 0.5% to 15.0%, immuno-monotherapy increased from 0.6% to 10.2%, and RT + systemic therapy increased from 0.6% to 2.5%. RT utilization remains low in the involved-site RT and rituximab era.
Keyphrases
- early stage
- low grade
- high grade
- diffuse large b cell lymphoma
- sentinel lymph node
- end stage renal disease
- healthcare
- newly diagnosed
- ejection fraction
- hodgkin lymphoma
- chronic kidney disease
- palliative care
- radiation therapy
- randomized controlled trial
- squamous cell carcinoma
- chronic lymphocytic leukemia
- peritoneal dialysis
- quality improvement
- radiation induced
- patient reported outcomes
- cell therapy
- replacement therapy
- drug induced